Altimmune, Inc. (NASDAQ:ALT) Receives $20.00 Average PT from Analysts

Shares of Altimmune, Inc. (NASDAQ:ALT) have been assigned an average recommendation of “Moderate Buy” from the eight brokerages that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $20.00.

Several research firms have recently weighed in on ALT. UBS Group started coverage on Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Altimmune in a research report on Thursday, November 14th.

Altimmune Stock Up 3.5 %

Altimmune stock opened at $8.18 on Friday. The company has a 50 day moving average of $7.89 and a 200-day moving average of $7.10. Altimmune has a twelve month low of $5.28 and a twelve month high of $14.84. The stock has a market capitalization of $581.80 million, a PE ratio of -5.28 and a beta of 0.15.

Altimmune (NASDAQ:ALT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. The firm had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same period in the previous year, the company posted ($0.39) earnings per share. Equities analysts anticipate that Altimmune will post -1.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD increased its position in shares of Altimmune by 13.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,238 shares of the company’s stock worth $156,000 after purchasing an additional 1,821 shares during the last quarter. B. Riley Wealth Advisors Inc. grew its stake in shares of Altimmune by 12.9% in the third quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company’s stock valued at $144,000 after buying an additional 2,687 shares in the last quarter. Creative Planning increased its holdings in Altimmune by 20.5% during the third quarter. Creative Planning now owns 18,411 shares of the company’s stock worth $113,000 after buying an additional 3,132 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Altimmune by 2.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock valued at $1,299,000 after acquiring an additional 4,772 shares during the period. Finally, Larson Financial Group LLC acquired a new position in shares of Altimmune during the 3rd quarter worth about $31,000. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.